Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Common Equity (2019 - 2025)

Historic Common Equity for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $37000.0.

  • Legend Biotech's Common Equity changed 0.0% to $37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $37000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $37000.0 for FY2024, which is 277.78% up from last year.
  • Legend Biotech's Common Equity amounted to $37000.0 in Q3 2025, which was down 0.0% from $37000.0 recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Common Equity peaked at $744.3 million during Q4 2022, and registered a low of $27.0 during Q1 2021.
  • For the 5-year period, Legend Biotech's Common Equity averaged around $43.8 million, with its median value being $36000.0 (2023).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 240090645.16% in 2022, then crashed by 9999.52% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's Common Equity stood at $31000.0 in 2021, then surged by 2400906.45% to $744.3 million in 2022, then plummeted by 100.0% to $36000.0 in 2023, then increased by 2.78% to $37000.0 in 2024, then changed by 0.0% to $37000.0 in 2025.
  • Its last three reported values are $37000.0 in Q3 2025, $37000.0 for Q2 2025, and $37000.0 during Q1 2025.